--- title: "Adjuvant Triple Negative Breast Cancer Ascent-05 | Sutter Health" description: "A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Triple Negative Breast Cancer Ascent-05 # Adjuvant Triple NegativeBreast Cancer Ascent-05 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05633654). #### Locations - Berkeley - Sacramento - Santa Barbara #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy ![Uma Suryadevara, M.D.](https://dyn.mktgcdn.com/p/uTm9De_Et4uRHg7A6rYTiaGafphjbp8QnGTH11anoUI/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Uma Suryadevara, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/uma-suryadevara-md-1049681015) ![Nitin Rohatgi, M.D., MBA](https://dyn.mktgcdn.com/p/tVS4RemP6bkC55e_mitBU2bV-F97uZqUB_hdGp4TZ6s/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Nitin Rohatgi, M.D., MBA Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017) ![Maira P Campos, M.D., MPH](https://dyn.mktgcdn.com/p/O8kWQsbunl3iLmbF4VNZnIoDKE_Ea6n5iIIs70R1lYg/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Maira P Campos, M.D., MPH Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/maira-p-campos-md-mph-1096705760) ## Email us to enroll - [Email Berkeley](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Triple%20NegativeBreast%20Cancer%20Ascent-05%20in%20Berkeley&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Triple%20NegativeBreast%20Cancer%20Ascent-05%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Santa Barbara](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Triple%20NegativeBreast%20Cancer%20Ascent-05%20in%20Santa%20Barbara&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Breast Cancer A012103 OptimiCE-PCR](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-cancer-a012103-optimice-pcr-1094794503) OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Breast Cancer ER-pos/HER2-neg EA1242](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-cancer-er-pos-her2-neg-ea1242-2072227055) A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS≤25 (RxFINE-Low) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Breast NRG-BR009](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-nrg-br009-1049142000) A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) **Status:** Open to Enrollment - Clinical trial ### [Advanced Breast Cancer HR+ HER2- WO45654](https://www.sutterhealth.org/research/clinical-trials/advanced-breast-cancer-hr-her2-wo45654-2044043570) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced or Metastatic Breast Cancer C4551002](https://www.sutterhealth.org/research/clinical-trials/advanced-or-metastatic-breast-cancer-c4551002-2060622373) An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Triple Negative Breast Cancer Ascent-05"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141#medicalwebpage","name":"Adjuvant Triple NegativeBreast Cancer Ascent-05","description":"A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141#breadcrumblist"},"mentions":[{"@type":"Person","name":"Uma Suryadevara, M.D.","url":"https://www.sutterhealth.org/research/investigators/uma-suryadevara-md-1049681015","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}},{"@type":"Person","name":"Nitin Rohatgi, M.D., MBA","url":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}},{"@type":"Person","name":"Maira P Campos, M.D., MPH","url":"https://www.sutterhealth.org/research/investigators/maira-p-campos-md-mph-1096705760","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141#medicaltrial","name":"Adjuvant Triple NegativeBreast Cancer Ascent-05","alternateName":"A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141","description":"A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy","identifier":"NCT05633654","code":{"@type":"MedicalCode","codeValue":"NCT05633654","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT05633654","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Breast Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Berkeley"},{"@type":"AdministrativeArea","name":"Sacramento"},{"@type":"AdministrativeArea","name":"Santa Barbara"}]} ```